Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen a significant stock price increase, with a recent rise of over 8%, attributed to strong mid-year performance and strategic initiatives in AI technology for medical aesthetics [1] Financial Performance - The company reported a revenue of 1.15 billion HKD for the first half of the year, representing a year-on-year growth of 20.7% [1] - The overall gross margin improved to 66.1%, an increase of 2 percentage points compared to the previous year [1] - Research and development expenses decreased by 21.9% to 150 million HKD, a reduction of 43 million HKD year-on-year [1] - The company achieved a net profit of 66 million HKD, with a net profit attributable to shareholders of 103 million HKD, marking a turnaround from losses in the previous year [1] Strategic Initiatives - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Pharmaceutical to promote the deep application and industrialization of AI technology in the development of medical aesthetic products [1] - The collaboration will lead to the establishment of an AI research and development company, indicating a significant step in the company's strategic layout in the "AI + Medical Aesthetics" innovation sector [1]
港股异动 | 四环医药(00460)再涨超8% 上半年实现扭亏为盈 AI+医美战略布局进入实质性阶段